Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout

Shingles Vaccine Not the Only Immunization Linked with Gout Flare

Marilynn Larkin  |  August 21, 2019

NEW YORK (Reuters Health)—The recombinant shingles vaccine (RZV) is associated with an increased risk of gout flare, and a new study suggests other vaccines may trigger flares as well, researchers say. “Our findings are novel because for the first time, we have identified a trigger for gout flares that presumably acts through [an inflammatory] pathway,…

Filed under:ConditionsGout and Crystalline Arthritis

Case Report: Not All Crystals Are Gout

Katherine Yates, MD, Erin H. Penn, MD, & Minna J. Kohler, MD   |  August 16, 2019

Patients with chronic kidney disease (CKD) often experience joint pain due to various etiologies, including crystalline arthropathies, renal osteodystrophy, amyloid arthropathy, erosive osteoarthritis, avascular necrosis and even erosive spondylarthrosis.1 Below, we present a case of crystalline arthropathy in a patient with chronic kidney disease, mistaken for gout. The Case A 29-year-old man was admitted to…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:chronic kidney diseasecrystal arthropathiesGout

Opioids Commonly Prescribed for Gout Attacks

Reuters Staff  |  July 9, 2019

NEW YORK (Reuters Health)—Nearly three in 10 patients seeking care at the emergency department (ED) for acute gout will be discharged with a prescription for opioids, new research shows. “Our study suggests a high use of prescription opioid in patients discharged from the ED with a diagnosis of gout, a condition that can be managed…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis Care & ResearchEmergency DepartmentGoutopioidPainPain Management

Contemporary Prevalence of Gout & Hyperuricemia in the U.S.

Arthritis & Rheumatology  |  May 31, 2019

Using 2007–2016 data from NHANES, a nationally representative survey of American men and women, Chen-Xu et al. set out to estimate the current prevalence rates and decadal trends of gout and hyperuricemia in the U.S.

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis & RheumatologyGouthyperuricemiaResearchurate-lowering therapies

The ACR’s & EULAR’s Gout Guidelines Include Treatment Approaches

Mary Beth Nierengarten  |  May 18, 2019

SNOWMASS VILLAGE, COLO.—The 2019 ACR Winter Rheumatology Symposium featured a session on gout. Despite a good understanding of its pathogenesis and the many effective therapies to treat it, gout remains a major public health problem in the U.S. Ann K. Rosenthal, MD, Will and Cava Ross professor of medicine and chief of the Division of…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinollesinuradProbenecidurate-lowering therapies

Gout & Sexual Function

Lara C. Pullen, PhD  |  April 22, 2019

Pain, physical disability and joint deformity have been linked to sexual dysfunction. New research suggests gout may also significantly affect relationships and intimacy. The study found the physical effects of gout on intimacy, such as joint pain, were the top-ranked concern for gout patients…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:disabilityGoutintimacysex

Research Is Advancing Our Understanding of Gout & Hyperuricemia

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The Gout and Hyperuricemia scientific session at the 2018 ACR/ARHP Annual Meeting opened with a talk by Tony R. Merriman, PhD, a research professor at the University of Otago, New Zealand. His talk focused on molecular epidemiology, with an emphasis on the interactions between genes and environmental exposures, and their contributions to gout. Dr. Merriman…

Filed under:ConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingGoutHuman Functional Genomics Projectshyperuricemia

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

Ruth Jessen Hickman, MD  |  March 18, 2019

Results of a recent study in Arthritis & Rheumatology fail to clarify whether urate-lowering therapies may potentially reduce mortality risk in patients with gout.1 The study also underscores the fact that many physicians are not following the ACR guideline to help their patients achieve target serum urate levels. Partly because of this, it remains unclear…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Allopurinolurate-lowering therapies

FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare

Michele B. Kaufman, PharmD, BCGP  |  March 12, 2019

The FDA has issued a boxed warning for febuxostat after a safety study found an increased risk of heart-related and other death in RA patients…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:cardiovascularColchicineDrug SafetyFebuxostatFood and Drug AdministrationGoutSafetyU.S. Food and Drug Administration (FDA)

Coding Corner Question: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

A 60-year-old man returns for a follow-up related to his diagnoses of rheumatoid arthritis and chronic gout of his right ankle and foot, without tophi. He reports the gout flares have subsided in his ankle. He takes 450 mg of allopurinol daily. He has rheumatoid factor-positive rheumatoid arthritis, which previously affected multiple sites, without organ…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisRheumatoid Arthritis Tagged with:Current Procedural Terminology (CPT) codesGout

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 59
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences